Literature DB >> 3693899

Immunochemical studies of Lolium perenne (rye grass) pollen allergens, Lol p I, II, and III.

A A Ansari1, T K Kihara, D G Marsh.   

Abstract

It was reported earlier that human immune responses to three perennial rye grass (Lolium perenne) pollen allergens, Lol p I, II, and III, are associated with histocompatibility leukocyte antigen (HLA)-DR3. Rye-allergic people are often concordantly sensitive to all three of these allergens. Since earlier studies suggested that these antigens are non-cross-reactive, their immunologic relatedness by double antibody radioimmunoassay (DARIA) was studied in order to understand further the immunochemical basis for the concordant recognition of the three allergens. Direct binding DARIA studies were performed with human sera from 189 allergic subjects. Inhibition DARIA studies were carried out with 17 human sera from grass-allergic patients who were on grass immunotherapy, one goat anti-serum, and six rabbit antisera. None of the sera detected any significant degree of two-way cross-reactivity between Lol p I and II, or between Lol p I and III. However, the degree of two-way cross-reactivity between Lol p II and III exhibited by individual human and animal antisera varied between undetectable and 100%. In general, the degree of cross-reactivity between Lol p II and III was higher among human sera than among animal sera. Taken together with earlier findings that antibody responses to Lol p I, II and III are associated with HLA-HDR3, and that most Lol p II and III responders are also Lol p I responders, but not vice versa, our present results suggest the following: the HLA-DR3-encoded Ia molecule recognizes a similar immunodominant Ia recognition site (agretope) shared between Lol p I and Lol p II and/or III; in addition, Lol p I appears to contain unique Ia recognition site(s) not present in Lol p II and III. However, further epitope analyses are required to investigate these possibilities.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3693899

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

1.  Molecular basis of cross-reactivity among allergen-specific human T cells: T-cell receptor V alpha gene usage and epitope structure.

Authors:  S S Mohapatra; S Mohapatra; M Yang; A A Ansari; P Parronchi; E Maggi; S Romagnani
Journal:  Immunology       Date:  1994-01       Impact factor: 7.397

Review 2.  Immunobiology of grass pollen allergens.

Authors:  Shyam S Mohapatra; Richard F Lockey; Shawna Shirley
Journal:  Curr Allergy Asthma Rep       Date:  2005-09       Impact factor: 4.806

3.  Crystal structure and activities of EXPB1 (Zea m 1), a beta-expansin and group-1 pollen allergen from maize.

Authors:  Neela H Yennawar; Lian-Chao Li; David M Dudzinski; Akira Tabuchi; Daniel J Cosgrove
Journal:  Proc Natl Acad Sci U S A       Date:  2006-09-19       Impact factor: 11.205

4.  Recombinant pollen allergens from Dactylis glomerata: preliminary evidence that human IgE cross-reactivity between Dac g II and Lol p I/II is increased following grass pollen immunotherapy.

Authors:  A M Roberts; R Van Ree; S M Cardy; L J Bevan; M R Walker
Journal:  Immunology       Date:  1992-07       Impact factor: 7.397

5.  Human T-cell responses to ragweed allergens: Amb V homologues.

Authors:  S K Huang; D G Marsh
Journal:  Immunology       Date:  1991-07       Impact factor: 7.397

6.  Allergen- and bacterial antigen-specific T-cell clones established from atopic donors show a different profile of cytokine production.

Authors:  P Parronchi; D Macchia; M P Piccinni; P Biswas; C Simonelli; E Maggi; M Ricci; A A Ansari; S Romagnani
Journal:  Proc Natl Acad Sci U S A       Date:  1991-05-15       Impact factor: 11.205

7.  High-resolution crystal structure and IgE recognition of the major grass pollen allergen Phl p 3.

Authors:  S C Devanaboyina; C Cornelius; C Lupinek; K Fauland; F Dall'Antonia; A Nandy; S Hagen; S Flicker; R Valenta; W Keller
Journal:  Allergy       Date:  2014-10-06       Impact factor: 13.146

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.